
Maria Chiara Tronconi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9532325/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial. Journal of Clinical Oncology, 2011, 29, 2773-2780.	0.8	702
2	Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. Journal of Hepatology, 2012, 57, 101-107.	1.8	191
3	Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Annals of Oncology, 2013, 24, 406-411.	0.6	126
4	A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology, 2015, 26, 542-547.	0.6	96
5	Clinical Outcome of Hypofractionated Stereotactic Radiotherapy for Abdominal Lymph Node Metastases. International Journal of Radiation Oncology Biology Physics, 2011, 81, 831-838.	0.4	81
6	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Technology in Cancer Research and Treatment, 2017, 16, 295-301.	0.8	80
7	Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. European Journal of Cancer, 2010, 46, 2746-2752.	1.3	41
8	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. Clinical Colorectal Cancer, 2019, 18, 125-132.e2.	1.0	35
9	Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1179-1187.	1.2	34
10	A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Oncologist, 2013, 18, 379-380.	1.9	34
11	Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial. Annals of Surgical Oncology, 2012, 19, 2256-2263.	0.7	30
12	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 2016, 5, 256-264.	1.3	29
13	Rectal squamous cell carcinoma treated with chemoradiotherapy: report of six cases. International Journal of Colorectal Disease, 2010, 25, 1435-1439.	1.0	25
14	Final results of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer Journal of Clinical Oncology, 2016, 34, 3521-3521.	0.8	25
15	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. Oncologist, 2019, 24, 385-393.	1.9	23
16	Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection. Journal of Clinical Oncology, 2011, 29, e680-e681.	0.8	17
17	Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. Clinical Colorectal Cancer, 2018, 17, e489-e498.	1.0	16
18	Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. British Journal of Radiology, 2017, 90, 20170257.	1.0	14

#	Article	IF	CITATIONS
19	FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: AÂPhase II Study. Clinical Colorectal Cancer, 2015, 14, 162-169.	1.0	11
20	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. Frontiers in Oncology, 2020, 10, 1652.	1.3	10
21	Chemotherapy with Mitomycin C and Capecitabine in Patients with Advanced Colorectal Cancer Pretreated with Irinotecan and Oxaliplatin. Tumori, 2006, 92, 285-289.	0.6	9
22	UFT as Maintenance Therapy in Patients with Advanced Colorectal Cancer Responsive to the FOLFOX4 Regimen. Oncology, 2007, 72, 267-273.	0.9	9
23	An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?. Anti-Cancer Drugs, 2010, 21, 459-464.	0.7	8
24	Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. Digestive and Liver Disease, 2011, 43, 225-230.	0.4	8
25	Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). Future Oncology, 2019, 15, 4009-4017.	1.1	8
26	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 2017, 20, 428-437.	2.7	5
27	Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis. Frontiers in Oncology, 2020, 10, 563404.	1.3	4
28	Analysis of early distant metastases of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer Journal of Clinical Oncology, 2016, 34, e15149-e15149.	0.8	1
29	Reply to Y. Pointreau et al. Journal of Clinical Oncology, 2012, 30, 335-335.	0.8	Ο